LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

ALT/AST Ratio Is an Independent Risk Factor for Gestational Diabetes Mellitus

By LabMedica International staff writers
Posted on 02 Feb 2022
Print article
Image: The Beckman AU5800 automatic analyzer (Photo courtesy of Beckman Coulter)
Image: The Beckman AU5800 automatic analyzer (Photo courtesy of Beckman Coulter)
Gestational diabetes mellitus (GDM) is defined as a state of impaired glucose tolerance first being discovered during pregnancy. GDM increases the risk of pregnancy complications and adverse perinatal outcomes, such as pregnancy-induced hypertension, preeclampsia, abortion, premature delivery, premature ruptures of membranes, and large for gestational age infants.

GDM also increases the risk of type 2 diabetes (T2DM) for mother in the future and influences the metabolism of offspring in the long run, bringing both public health and economic burden. Aspartate aminotransferase-to-alanine transaminase ratio (AST/ALT) has been reported not only an assessment tool of hepatic diseases, but also a valuable prognostic tool for cardiovascular disease, arterial stiffness, cancers, and chronic kidney disease. Recently it has been of great interest as a possible novel marker for metabolic syndrome and insulin resistance.

Endocrinologists at the Peking Union Medical College Hospital (Beijing, People’s Republic of China) and their colleagues included in a prospective, double-center, observational cohort study, a total of 1,128 pregnant women. Blood samples were collected at the first prenatal visit and 75-gram oral glucose tolerance test (OGTT) was conducted for all participants during 24 to 28 weeks of gestation. Biochemical parameters presented in the present study, including ALT, AST, total bilirubin (TBil), total cholesterol (TC), triglycerides (TG), low and high density lipoprotein cholesterol (LDL-C, HDL-C), were measured by Beckman AU5800 automatic analyzer (Beckman Coulter, Brea, CA, USA). Quality controls were performed by Bio-Rad biochemical quality control product (Bio-Rad Laboratories, Hercules, CA, USA).

The investigators reported that the incidence of GDM was 22.07% (249/1,128). ALT/AST ratio was higher in GDM group than in NGT group (0.92 versus 0.80). ALT/AST had positive correlations with fasting blood glucose, 1-hour and 2-hour blood glucose concentration during OGTT (0.089, 0.176, and 0.115, respectively). The odds ratio (OR) of ALT/AST for incidence of GDM was 1.603. The ROC-AUC of ALT/AST and TG/HDL-C reached 0.615 and 0.619, respectively.

The authors concluded that higher ALT/AST in early pregnancy, even within the normal range, was an independent risk factor of GDM. ALT/AST presented similar predictive ability to TG/HDL-C for GDM in this cohort study. The study was published on January 5, 2022 in the International Journal of General Medicine.

Related Links:
Peking Union Medical College Hospital
Beckman Coulter
Bio-Rad Laboratories


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.